Evidence map›Paper›PMID 42911238›Full record

ArticleActa neuropathologica2026

TSPO-PET binding in vivo reflects increased phagocytic microglia at post mortem in people with frontotemporal dementia.

Davi S Vontobel, Kei Onn Lai, Mehtap Bacioglu, George Nolan, Daniel C Maddison, Amelie Adamski, Julia Goddard, Noah L Shapiro, Harry Crook, Tim Fryer and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neuropathologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Davi S VontobelDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Kei Onn LaiDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Mehtap BaciogluDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
George NolanDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Daniel C MaddisonDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Amelie AdamskiDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Julia GoddardDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Noah L ShapiroDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Harry CrookDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Tim FryerDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Young HongDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Sasvi WijesingheDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Franklin AigbirhioDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Edward AvezovDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Kieren S J AllinsonDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Annelies QuaegebeurDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
John T O'BrienDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
James B Rowe *Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Maria Grazia Spillantini *Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Maura Malpetti *Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. mm2243@medschl.cam.ac.uk.

Funding

Alzheimer's Research UK PhD Scholarships ARUK-PhD2023-018; 2024-006Alzheimer's Society 694Dementias Platform UK; Medical Research Council MC_UU_00030/14; MR/T033371/1Kissick Family Foundation Frontotemporal Dementia Grant Program KFF-FTD-3449204717National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre BRC-1215-20014; NIHR203312Race Against Dementia; Alzheimer's Research UK ARUK-RADF2021A-010the Cambridge University Centre for Parkinson-Plus RG95450UK Dementia Research Institute UKDRI-2203Wellcome Trust 103838; 220258
6 · The paper itself

Abstract

Brain inflammation is a key feature of frontotemporal dementia (FTD). Positron emission tomography (PET) of the 18 kDa translocator protein (TSPO) is widely used as an in vivo proxy for neuroinflammation, but whether the elevated signal reflects microglial, astrocytic or vascular pathology remains controversial, and this has not previously been resolved in FTD using matched ante mortem imaging and post-mortem tissue. We paired ante mortem [

Indexed as

BrainFrontotemporal DementiaMicrogliaReceptors, GABAAgedAged, 80 and overAntigens, CDAntigens, Differentiation, MyelomonocyticCD68 MoleculeFemaleHumansIsoquinolinesMaleMiddle AgedPositron-Emission TomographyAntigens, CDAntigens, Differentiation, MyelomonocyticCD68 antigen, humanCD68 MoleculeIsoquinolinesReceptors, GABATSPO protein, humanCD68Frontotemporal dementiaMicrogliaNeuroinflammationPost-mortem neuropathologyTSPO–PET

Identifiers

PMID42911238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.